Bavarian Nordic A/S (BAVA.CO)

157.00 +1.30 (+0.83%) 收市：04:59PM CEST

Bavarian Nordic A/S

Philip Heymans Alle 3
Hellerup 2900
Denmark
45 33 26 83 83
https://www.bavarian-nordic.com

版塊: Healthcare
行業: Biotechnology
全職員工: 1,381

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Paul John Chaplin MSc, Ph.D.	CEO & President	14.62M	無	1967
Mr. Henrik Juuel M.Sc.	CFO & Executive VP	8.09M	無	1965
Mr. Russell Thirsk M.Sc.	Executive VP & COO	無	無	1968
Mr. Rolf Sass Sørensen	Vice President of Investor Relations & Communications	無	無	無
Ms. Anu Helena Kerns M.Sc.	Executive VP and Chief People & Sustainability Officer	無	無	1972
Mr. Jean-Christophe May M.B.A., Pharm.D.	Executive VP & Chief Commercial Officer	無	無	1967

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 DKK。

描述

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

公司管治

截至 2024年6月1日 止，Bavarian Nordic A/S 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中：4；董事會：1；股東權利：1；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。